Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hofseth Biocare ASA ( (HOFBF) ) has issued an announcement.
Hofseth BioCare ASA’s ProGo® has been recognized for its unique ability to activate GLP-1 and GIP receptors, contributing to weight loss and improved metabolism, as evidenced by clinical studies. This recognition highlights the product’s potential impact on consumer health and medical nutrition, enhancing the company’s market positioning and stakeholder interest.
More about Hofseth Biocare ASA
Hofseth BioCare ASA is a Norwegian company focused on consumer and pet health, emphasizing sustainability and optimal use of natural resources. The company upcycles salmon industry by-products into health-improving ingredients such as ProGo®, OmeGo®, and CalGo®, which offer various health benefits including improved metabolism, immune health, and bone and joint support.
Average Trading Volume: 58,711
Current Market Cap: NOK711.2M
See more insights into HOFBF stock on TipRanks’ Stock Analysis page.